The invention described herein provides high throughput methods and reagents for generating transgenic animals (e.g., mammals) through introducing materials into gametes or preimplantation stage (e.g., one-cell embryo or zygotes) via electroporation, leading to genetically inheritable modification to the genome of the animal.

The invention described herein provides high throughput methods and reagents for generating transgenic animals (e.g., mammals) through introducing materials into gametes or preimplantation stage (e.g., one-cell embryo or zygotes) via electroporation, leading to genetically inheritable modification to the genome of the animal.

Semen and sperm cell processing and preservation systems, and methods of producing a mammal and methods of producing mammalian embryos are disclosed. The present invention is directed to sperm cell preservation, fertilization, and insemination, maintaining or enhancing sperm quality and addressing one or more sperm cell characteristics, such as viability, motility, functionality, fertilization rates, and pregnancy rates. Further, sperm cell characteristics may be addressed within the context of various collection, handling, separation, storage, transportation, usage, fertilization, or insemination techniques.

Semen and sperm cell processing and preservation systems, and methods of producing a mammal and methods of producing mammalian embryos are disclosed. The present invention is directed to sperm cell preservation, fertilization, and insemination, maintaining or enhancing sperm quality and addressing one or more sperm cell characteristics, such as viability, motility, functionality, fertilization rates, and pregnancy rates. Further, sperm cell characteristics may be addressed within the context of various collection, handling, separation, storage, transportation, usage, fertilization, or insemination techniques.

The present invention relates to processes for transfecting cells. In particular, the present invention relates to processes for using CRISPR to incorporate a polynucleotide into the genome of an avian primordial germ cell (PGC).

The present invention relates to processes for transfecting cells. In particular, the present invention relates to processes for using CRISPR to incorporate a polynucleotide into the genome of an avian primordial germ cell (PGC).

The invention relates to a carrying device for beverage cans which allows the manual carrying of beverage cans grouped together in the form of a “pack”, which device comprises a body devoid of side walls, having on its surface at least one opening defining a contour with proportions which allow the tight passage therethrough of a beverage can, the contour of said opening having a plurality of tabs that can be folded or bent in relation to the body itself and extending into the same opening, said tabs having a distribution according to at least one sequence, said sequence comprising two contiguous tabs followed by a gap followed by another tab followed by another gap.

The present disclosure belongs to the technical field of bioengineering, and relates to a method for constructing a Ptgds gene knockout rat model with spontaneous kidney yin deficiency. The method includes the following steps: 1) designing target sequences Ptgds-sgRNA1/2; 2) purifying Cas9mRNA and the Ptgds-sgRNA1/2; 3) conducting targeted knockout on a sequence fragment in the Ptgds gene using a CRISPR/Cas9 system; 4) injecting the purified Cas9mRNA, the purified Ptgds-sgRNA1/2, and a Ptgds knockout gene into rat embryos to obtain neonatal rats; 5) conducting genetic identification to select heterozygous rats; and 6) conducting breeding on the heterozygous rats with wild-type rats for multiple generations to obtain the Ptgds gene knockout rat model. In the present disclosure, the method has a high accuracy of gene modification, a targeting specificity, and a short experimental period.

The present disclosure belongs to the technical field of bioengineering, and relates to a method for constructing a Ptgds gene knockout rat model with spontaneous kidney yin deficiency. The method includes the following steps: 1) designing target sequences Ptgds-sgRNA1/2; 2) purifying Cas9mRNA and the Ptgds-sgRNA1/2; 3) conducting targeted knockout on a sequence fragment in the Ptgds gene using a CRISPR/Cas9 system; 4) injecting the purified Cas9mRNA, the purified Ptgds-sgRNA1/2, and a Ptgds knockout gene into rat embryos to obtain neonatal rats; 5) conducting genetic identification to select heterozygous rats; and 6) conducting breeding on the heterozygous rats with wild-type rats for multiple generations to obtain the Ptgds gene knockout rat model. In the present disclosure, the method has a high accuracy of gene modification, a targeting specificity, and a short experimental period.

Immunocompatible pluripotent stem cells (pSCs), which include cells compatible with different patient populations or patient-specific cells, find wide application in regenerative medicine therapies. Described herein are immunocompatible pSCs generated using techniques such as parthenogenesis resulting in cells possessing desired haplotypes of reduced zygosity, antigenically compatible with multiple patient populations, or nuclear transfer allowing generation of patient-specific cells. Methods described herein related to parthenogenesis, nuclear transfer, or pSC cell line generation. Also described herein are compositions of immunocompatible pSCs and cell lines generated by the aforementioned techniques.